Diginex launches supply chain due diligence solution
Diginex Limited (NASDAQ: DGNX) announced the integration of Risk-to-Remedy, an end-to-end supply chain due diligence solution, according to a company press release.
The London-based ESG and compliance solutions provider built the product on its existing LUMEN risk assessment platform and APPRISE worker engagement tool. The company strengthened the offering through its acquisition of The Remedy Project's expertise in grievance mechanisms and remediation.
Risk-to-Remedy combines worker-level evidence, remediation processes and regulatory reporting within a single framework. The solution addresses compliance requirements under various regulations including the UK Modern Slavery Act, Australia's Modern Slavery Act, Canada's Fighting Against Forced Labour Act, the CSDDD, the German Supply Chain Due Diligence Act, and the EU Forced Labour Regulation.
The company cited market research indicating the human rights and supply chain due diligence market was valued at approximately $3.8 billion in 2025 and is projected to reach $9.6 billion by 2034.
Diginex plans additional enhancements to its supply chain offering. The upcoming features will enable clients to manage assessments and audits, collect supporting evidence, monitor non-compliance and corrective actions, and maintain regulatory records.
The company noted that 86% of forced labor occurs in the private sector and modern slavery affects an estimated 50 million people globally. Current compliance tools typically rely on supplier declarations and annual audits that may not capture worker experiences.
Diginex provides ESG, sustainability and compliance solutions to institutional and corporate clients. The company's platform utilizes blockchain, artificial intelligence, machine learning and data analysis technology for corporate regulatory reporting and sustainable finance applications.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Fusion receives Texas certification for its fusion engine models
- Silo Pharma, Inc. (SILO) files for 1.91M share offering by selling stockholders
- Waymo Explores Split With Uber - FT
Create E-mail Alert Related Categories
Corporate NewsRelated Entities
Definitive Agreement, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share